- Research article
- Open Access
Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice
© Jia et al. 2017
- Received: 12 June 2017
- Accepted: 23 November 2017
- Published: 14 December 2017
Intestinal bacteria are known to regulate bile acid (BA) homeostasis via intestinal biotransformation of BAs and stimulation of the expression of fibroblast growth factor 19 through intestinal nuclear farnesoid X receptor (FXR). On the other hand, BAs directly regulate the gut microbiota with their strong antimicrobial activities. It remains unclear, however, how mammalian BAs cross-talk with gut microbiome and shape microbial composition in a dynamic and interactive way.
We quantitatively profiled small molecule metabolites derived from host-microbial co-metabolism in mice, demonstrating that BAs were the most significant factor correlated with microbial alterations among all types of endogenous metabolites. A high-fat diet (HFD) intervention resulted in a rapid and significant increase in the intestinal BA pool within 12 h, followed by an alteration in microbial composition at 24 h, providing supporting evidence that BAs are major dietary factors regulating gut microbiota. Feeding mice with BAs along with a normal diet induced an obese phenotype and obesity-associated gut microbial composition, similar to HFD-fed mice. Inhibition of hepatic BA biosynthesis under HFD conditions attenuated the HFD-induced gut microbiome alterations. Both inhibition of BAs and direct suppression of microbiota improved obese phenotypes.
Our study highlights a liver–BA–gut microbiome metabolic axis that drives significant modifications of BA and microbiota compositions capable of triggering metabolic disorders, suggesting new therapeutic strategies targeting BA metabolism for metabolic diseases.
- Bile acids
- High-fat diet
- Gut microbiota
- Microbe-metabolite interaction
There is growing concern that environmental factors, especially the ‘Western’ high-fat diet (HFD), have altered the genetic composition and metabolic activity of the mammalian gut microbiome [1, 2], predominantly through changes in the relative abundance of two dominant bacterial divisions, Firmicutes and Bacteroidetes. At the level of class and below, dramatic overgrowth of Staphylococcus aureus and Enterobacteriaceae (including E. coli) was observed in obese subjects . The animal-based diet increased the abundance of Alistipes, Bilophila, and Bacteroides and decreased the levels of Roseburia, Eubacterium rectale, and Ruminococcus bromii, which metabolize dietary plant polysaccharides . Recent studies have begun to focus on the effects of dietary interventions in reshaping the gut microbiota composition [1, 4]. However, much remains to be understood about designing and implementing treatments that are effective and adaptive in the mammalian gastrointestinal tract ecosystem. The gut microbiota composition is partially modulated by the extracellular metabolites that are derived from host and modified by microbes. Of these, bile acids (BAs) represent a highly abundant pool of host-derived and microbial-modified metabolites that are major regulators of the gut microbiome .
HFD-induced BA secretion as a driving force in shaping the obesity-associated gut microbial composition was first proposed in 2011 by Islam et al. , who observed that rats fed cholic acid (CA) experienced increases in Firmicutes accompanied by decreases in Bacteroidetes phyla; the resulting altered microbial signature was similar to that of obesity-associated gut microbiome. BAs are major constituents of bile, produced in the liver and then secreted into the duodenum to facilitate fat digestion and absorption . They are antibacterial and create strong selective forces for the intestinal microbiota [1, 7]. Even within a single bacterial species, there can be differential sensitivity to specific BAs [8, 9]. Diet fat content can regulate the time and amount of secreted bile  and thus shape the microbiota. The impact of BAs on gut microbial composition has also been highlighted in murine colitis models . Feeding mice a diet rich in milk-derived fat induced elevated levels of the BA taurocholic acid (TCA), facilitating the outgrowth of Bilophila wadsworthia, a bacteria species linked to the induction of colitis. Unfortunately, it remains unclear how the mammalian gut microbiome responds to short or long-term diet-induced changes in the BA pool. A systems-level understanding of microbe–microbe and microbe–metabolite interactions in the human gut is critical for understanding the potential limitations and opportunities of probiotic treatments. Probiotic treatments could potentially be useful in sequestering carcinogenic BAs and enriching those that exert beneficial effects on glucose and lipid metabolism in the host.
In the current study, we systematically evaluated the role of dietary fat-induced BA changes in shaping the gut microbial composition in male C57BL/6 mice. A global metabolome profiling of host–microbial co-metabolism implied BAs as a significant dietary factor that influenced changes in gut microbiota. HFD or BAs were administrated to mice and subsequent changes in both the BA pool and microbial compositions were profiled. Time-dependent profiles of gut microbiome responses to HFD were then monitored to determine the temporal relationship between BAs and alterations in the intestinal microbial composition. Additionally, microbiota changes were measured in response to the inhibition of hepatic BA biosynthesis. Our overall purpose was to establish a linkage between dietary fat, BAs, and specific alterations of the gut microbiome, which, in turn, would be capable of triggering metabolic disease. Identification of specific microbiota alterations in response to BAs may suggest new therapeutic strategies that target BA metabolism for the prevention and treatment of metabolic diseases.
Correlation of metabolome with gut microbiome in response to HFD treatment revealed that BAs were an important dietary factor impacting gut microbiota composition
To assess the interaction of BAs with caecal microbiota, we quantified the concentration of BAs in the caecal content of mice fed with control chow and HFD, and found that caecal BA levels were dramatically increased in response to HFD (Fig. 1b). Among the 42 quantified BAs, 35 had higher concentrations in the HFD group, including CA, glycocholic acid (GCA), taurodeoxycholic acid (TDCA), TCA, chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), taurochenodeoxycholic acid (TCDCA), β-muricholic acid (βMCA), lithocholic acid (LCA), and 7-ketolithocholic acid (7-ketoLCA), with statistical significance (Fig. 1c and Additional file 5: Table S4). Only one BA, β-cholic acid (βCA), was significantly decreased after a HFD intervention. All of the CA-derived BAs, including CA, TCA, and GCA, were significantly increased, implying that CA-derived BAs might be the important BA species in the response to dietary fat.
Dietary fat-induced gut microbiome alteration and its correlation with BAs
To visualize the correlation of BAs and gut microbiota, a Spearman correlation was performed between the relative abundance of the 10 differential microbial species and the concentrations of all BAs across the samples in the control and HFD groups (Fig. 2e and Additional file 10: Table S7). Among the 42 BAs shown in the heatmap, 33 had at least one significant correlation with a microbe. Most microbes in Bacteroidetes and Verrucomicrobia phyla were negatively correlated with BA changes, while those in Firumicutes and Proteobacteria phyla were positively correlated with BA changes.
How BAs alter the gut microbial composition
In order to determine the temporal relationship between BA exposure and alterations in intestinal microbial composition in response to HFD, we performed time-dependent studies on BAs and gut microbiome composition with HFD intervention. Mice fed with HFD or normal chow were sacrificed at different time points, i.e., at days 0, 0.5, 1, 2, 3, 6, 10, 28, and 56.
The concentrations of BAs and the abundance of gut microbes in both the control and HFD groups were compared at each corresponding time point. The concentrations of BAs, as well as all of the microbes at species and genus levels, were recorded when they were significantly altered at the earliest time point. The number of BAs reached a plateau after only 12 h of HFD intervention, indicating that a HFD rapidly stimulates BA secretion (Fig. 3c). However, there were no changes in the microbiota detected during this period. The number of microbes gradually increased and reached their highest value at D3. Such observations suggest that the response to BAs precedes and perhaps affects the gut microbiota response to the HFD intervention. Regarding the specific BAs (Fig. 3d and Additional file 12: Table S8), after 1 day of the HFD intervention, the concentration of 26 BAs were altered, and the concentrations of conjugated BAs TCA, TCDCA, tauro-α-muricholic acid (TαMCA), tauro-β-muricholic acid (TβMCA), GCA, and glycochenodeoxycholic acid (GCDCA) were increased. The unconjugated BAs could be sorted into two distinct groups conformed of most primary BAs, which had an increased concentration, and most secondary BAs, which had a decreased concentration. The concentrations of specific microbes, such as Bilophila spp., Blautia spp., Oscillospira spp., and Ruminococcus spp., were initially increased. The alteration of the microbial community in the caecum was then reshaped, with some species coming more prominent and others less so. After 10 days of the HFD intervention, all of the detected BAs had fluctuated, while two microbes were observed to be impacted at D28. The response of gut microbiota alteration lagged behind that of BA increase, implying that BAs might regulate the composition of gut microbiota.
BAs alone induce the obesity-associated gut microbial composition
To confirm that the HFD-induced gut microbial alterations were correlated with BAs, BAs were administered to mice under normal diet conditions. GCA and TCA were selected as the BA supplementation for two reasons. Firstly, CA-type BAs were significantly increased after the HFD intervention, implying the predominant role of these BAs is associated with dietary fat. Secondly, conjugated primary BAs were the main components of bile secreted to intestine in response to dietary fat.
We also observed that supplementation of BAs significantly changed the phenotype and biochemical parameters of mice (Fig. 4c and Additional file 1: Table S1), similarly to observations in the HFD study, i.e., increased body weight gain, fat mass, liver weight, and serum total cholesterol. The results confirmed the correlative relationship between phenotype alteration and BA administration.
The impact of BAs on the caecal microbiota composition was revealed by sequencing of 16S rRNA genes. The Simpson reciprocal index for gut microbiota alpha diversity was decreased in the control + BA group, even lower than that determined for the HFD group relative to the control group (Additional file 13: Figure S5). Microbial composition differences could be visualized in the PCOA plot (Fig. 4d), which reveals clear separation among all three groups. The distribution of the samples in the control + BA group were between those in the control and HFD groups, and had statistical significance along the PC1 axis compared to the control group. This indicated that the microbiota composition with normal chow had been altered with BA impact in a similar way as observed with a HFD. Consistently, the samples in the control + BA and HFD groups were clustered to the same node, separately from the control, except for one control sample (Fig. 4e). Thus, BA administration can directly alter gut microbial composition, mimicking the HFD intervention. Population analyses for each diet group were performed and the mean percentage of the total population at phylum levels is shown in Fig. 4f and Additional file 7: Table S5. The results showed that, relative to the control, the gastrointestinal microbiota in the control + BA group was characterized by a reduction in Bacteroidetes (26.22% to 23.53%) and an increase in Firmicutes (30.59% to 33.24%) although without statistical significance. Verrucomicrobia, which has relatively low abundance in the gut microbial composition, was significantly decreased in the control + BA group compared to the control. This decrease was similar to that observed for a HFD. The Proteobacteria phylum was increased after BA intervention but not after HFD treatment.
To visualize the impact of BAs on the 10 microbial species significantly changed by HFD, we compared the mean value of abundance of each microbe in the control, HFD, and control + BA groups. The results (Fig. 4b) in ‘Microbiome alteration’ showed that eight of the 10 microbes had the same alteration trend in the HFD and control + BA groups compared to the control. The alterations of Oscillospira spp. and Parabacteroides spp. were inconsistent, implying that the alterations of these two microbes by HFD might be due to other causes. The resulting microbial composition implied that the eight microbial species R. gnavus, Blautia spp., Allobaculum spp., Bilophila spp., Desulfovibrio spp., Prevotella spp., Bacteroides spp., and Akkermansia muciniphila, might be regulated by BAs in the obesity-associated gut microbiome.
We then performed a Spearman correlation between the BAs and the microbes in the control and control + BA groups. We observed that, except for Desulfovibrio spp., the rest of the seven microbes were significantly correlated with specific BAs (Fig. 4b and Additional file 14: Table S9). Thus, these seven microbes might be the bacteria that differentially respond to increases of a specific HFD-induced BA secretion.
BA reduction as a therapeutic option for attenuating HFD-induced gut microbiome alteration and obese phenotype
The HFD effects on obesity might be due to its effects on BA pool size. Therefore, we inhibited hepatic BA biosynthesis by using the synthetic farnesoid X receptor (FXR) agonist, GW4064 , in male C57BL/6 J mice. Meanwhile, to confirm that the impact of HFD-induced BA secretion on the obesity phenotype was regulated by gut microbiota, the broad-spectrum and non-absorbable antibiotic rifaximin was administered to mice under HFD conditions.
The mice fed with a HFD supplemented with GW4064 did not gain weight as rapidly as HFD controls based on their similar energy intake. Such intervention also induced a lower fat mass and liver weight. In addition, GW4064 supplementation counteracted the HFD-induced high serum total cholesterol. Similarly, we also observed a reduction in body weight, abdomen adipose tissue weight, liver weight, and serum total cholesterol concentration in the HFD + rifaximin group (Fig. 5b and Additional file 1: Table S1).
Gut microbiota fluctuated after GW4064 administration relative to the HFD group. The alpha diversity was significantly increased after GW4064-induced BA regulation (Additional file 15: Figure S6). A preliminary unweighted PCOA (Fig. 5c) was conducted to visualize differences in bacterial taxa composition and the trend indicated that the HFD + GW4064 group was closer to the controls than to those in the HFD group with statistical significance along the PC1 axis between the HFD and HFD + GW4064 groups. This implied that the composition of obesity-associated gut microbiota has been reversed towards the control state after BA regulation. The phylum bar plot also revealed that the composition of gut microbiota in HFD + GW4064 was similar to controls. The abundance of Firmicutes and Proteobacteria were decreased, while Bacteroidetes and Verrucomicrobia were increased in the HFD + GW4064 compared to HFD groups (Fig. 5d and Additional file 7: Table S5). Thus, utilization of an FXR agonist may prevent or reverse HFD-induced gut microbiome alterations and impair the development of obese phenotypes.
Diet can affect the intestinal microbiota composition and activity in various ways, including providing prebiotic substrates and other fermentable constituents, regulating transit time, pH, and host secretions, as well as influencing gene expression in both the host and microbiome . Based on the global metabolome analysis and multivariate statistics performed herein, BAs showed a predominant role in host–microbiota co-metabolism, confirming that BAs are a significant dietary factor influencing the composition of gut microbiota.
Previous reports have shown that a HFD changes the relative composition of gut microbiota by increasing Firmicutes and decreasing Bacteroidetes at phylum levels along with alterations of the microbes at species levels such as Bilophila and Bacteroides [1, 2, 7, 13]. Our results confirmed a similar shift in population between Bilophila spp., Firmicutes, and Bacteroidetes. The interaction of BAs and the gut microbiome is well-known ; however, herein, the link between exposure to specific types of BAs and specific changes in gut microbiota was revealed in a time course experiment that clearly demonstrated that the HFD-induced secretion of BAs into the intestine maximized at 12 h post-HFD and preceded the changes in microbiota, which maximized at 72 h. These results thus demonstrate that BAs are responsible for microbiota composition changes. Further confirmation for this effect of BAs came from our follow-up experiment, which reproduced the HFD phenotype via replacement of a HFD with BA feeding. To our knowledge, this type of time-dependent experiment correlating changes in BAs with those of microbiota has not been previously published.
Seven microbial species were found to have similar responses to both HFD and BA administration. Among these seven microbial species, three were increased with the HFD intervention, including Bilophila spp., Ruminococcus spp., and Blautia spp. increasing after 1 day of intervention and, specifically, R. gnavus increasing at day 3. Such alterations suggested that these three types of microbes were bile tolerant. On the other hand, the decrease in populations of Prevotella, Bacteroides, and Parabacteroides spp. as well as A. muciniphila implied that these bacteria were more sensitive to BAs.
Previous research  has shown that Bilophila wadsworthia was stimulated in mice by BA secretion. This microbe is a sulfite-reducing bacterium that thrives in the presence of TCA. A previous clinical study  also supported our results that Bilophila spp. growth in humans could be promoted by a HFD. The byproducts of Bilophila spp., H2S and secondary BAs, have been shown to perturb the immune homeostasis and induce colonic tissue damage, suggesting that the increase in Bilophila spp. might be involved in the pathogenesis of colonic diseases in obese individuals . Blautia spp. were found to be capable of 7α-dehydroxylation to produce the more anti-microbial secondary BAs from primary BAs . Secondary BAs are known to be high affinity ligands for FXR . BA activation of FXR downregulates BA synthesis and stimulates the synthesis of BA-detoxifying enzymes. Activated FXR can also bind directly to the pro-inflammatory transcription NF-κB and control intestinal inflammation. The increase in Blautia spp. after the first day may therefore play an important role as a compensating response to the presence of increased amounts of BAs in the gut [15–18]. R. gnavus has been reported to be an ursodeoxycholic acid (UDCA) producer as it produces 7β-hydroxysteroid dehydrogenase, an enzyme capable of degrading 7-ketoLCA to UDCA . Increased R. gnavus along with decreased levels of 7-ketoLCA and increased UDCA levels at day 1 were observed herein. UDCA is cytoprotective against secondary BAs such as DCA and has been previously shown to be able to inhibit DCA-induced activation of the EGFR/Raf-1/ERK signaling pathway in HCT-116 cells and in an azoxymethane mouse model for colorectal cancer [20, 21]. R. gnavus is also involved in the iso-BA pathway, which detoxifies secondary BAs producing iso-BAs with lower detergent and cytotoxic activities . Our data showed a positive correlation trend between increased R. gnavus and isolithocholic acid levels.
Four microbes were decreased in our study, A. muciniphila, Allobaculum spp., Desulfovibrio spp., and Prevotella spp., all of which are considered beneficial bacteria commonly higher in healthy relative to obese people [23–25]. A. muciniphila, a mucin-degrading bacterium, has been reported to exert an anti-obesogenic effect and has been shown to be significantly decreased in obese animals [23, 26]. Administration of A. muciniphila reversed HFD-induced fat-mass gain, metabolic endotoxemia, adipose tissue inflammation, and insulin resistance . Desulfovibrio spp. are also involved in mucin fermentation and found to be more abundant in normal weight children compared to those who are overweight . Allobaculum and Prevotella spp.  degrade dietary fiber to SCFAs, which serves as a main colonic energy source. Prevotella spp. help maximize energy extraction from a diet rich in fiber . The abundance of Allobaculum spp. was previously shown to be strongly inversely correlated with the amounts of circulating leptin and the expression of several genes correlated with energy expenditure, homeostasis, and inflammation.
Overall, our findings showed that the presence of increased populations of bacteria that are capable of deconjugating and producing secondary BAs in response to high concentrations of BAs may provide some protective compensation effects via increased potential for FXR activation and UDCA production. Simultaneously, there were decreased populations of beneficial microorganisms that are anti-obesogenic in response to increased BA exposure.
A previous study modified obese mouse phenotypes using probiotics , and provided evidence that stimulation of beneficial bacterial growth may occur along with depression of more harmful bacteria by lowering BA secretion through inhibition of BA biosynthesis. In the present study, the use of the FXR agonist GW4064 to inhibit BA biosynthesis prevented the development of the obese phenotype and its corresponding alteration of the gut microbial composition. Further, the HFD led to increased BA secretion into the gut, whereas the normal diet did not, thus a dietary intervention may also be effective in altering the obese phenotype.
The alteration trends of Bacteroides spp. varied between the short- and long-term HFD interventions. Bacteroides spp. concentrations were increased at day 2 but were low at 8 weeks. Previous reports revealed Bacteoriodes spp. as bile-tolerant microbes , becoming increased during the first several days following exposure to high levels of BAs. Our results indicated that BAs could have a varying selective pressure on the different bile tolerant microbes. Some microbes were resistant to apoptosis, and were even highly favored in the presence of high BA concentrations, whereas other microbes such as Actinobacter spp. showed an increased abundance only at low BA concentrations (day 28). With the high concentration of conjugated and primary BAs, those bacteria containing the enzymatic machinery for bile salt dehydrolase and dehydroxylation showed increased growth. The observed increase in hydrophobic secondary BAs, which are strong antimicrobial compounds, is a reasonable explanation for the suppression of beneficial bacteria that were bile intolerant.
The fact that all of the animal models used were male mice represents a limitation to the present study. Considering the sex-based differences in BA patterns and gut microbial composition, future studies on both sexes are required.
Our study provided a correlative relationship between BAs and the HFD-induced alteration of gut microbiota. Dietary intervention and FXR activation has been confirmed to play an important role in the treatment of obesity via a decrease in BA secretion and/or synthesis. Future studies will be needed to establish similar relationships between changes in both BA concentrations and composition and changes in the gut microbiota in human obese versus normal weight phenotypes. Ultimately, identification of key microorganisms may yield better probiotic therapeutics to replenish beneficial bacteria that have been lost by patients suffering from obesity and metabolic syndrome. The development of safe FXR agonists along with dietary consultation will translate our experimental findings into clinical practice.
Animal studies and sample collection
All animal studies were performed following national legislation and local guidelines at the Center for Laboratory Animals, Shanghai Jiao Tong University, Shanghai, China. C57BL/6 J mice (male, 3 weeks old) were purchased from Shanghai Laboratory Animal Co. Ltd. (SLAC, Shanghai, China) with 1 week of acclimatization. All experimental mice were housed in specific pathogen-free environments under a controlled condition of 12 h light/12 h dark cycle at 20–22 °C and 45 ± 5% humidity, with free access to chow and ultrapure water. The mice were randomly divided into groups for further experiments. The body weights and food intake of all animals were recorded once a week during the experiments. Mice were fasted overnight and then anesthetized for blood harvesting. The blood was centrifuged at 3,000 g for 15 min at 4 °C for serum collection. Livers, three types of white adipose tissues (epididymal, abdomen, and kidney adipose tissues), brown adipose tissues, and caecal content were carefully dissected and kept in liquid nitrogen before storage at −80 °C.
Animal experiment 1
Mice were divided into five groups (n = 7 per group as biological replicates) with different diets for 8 weeks: (1) control group, fed with normal chow (10% fat calories); (2) HFD group, fed with diet containing 45% fat calories from coconut oil; (3) control + BA group, fed with control chow supplemented with 1 mmol/kg GCA and TCA, respectively; (4) HFD + GW4064 group, fed with HFD supplemented with 180 mg/kg GW4064; and (5) HFD + rafiximin group, fed with HFD supplemented with 80 mg/kg antibiotic rafiximin. The feed ingredients of normal chow and HFD are provided in Additional file 16: Table S10.
Animal experiment 2
Mice were divided into 18 groups (n = 5 per group as biological replicates), of which nine were fed with normal chow and nine were fed a HFD. Two groups of mice, one each for the different diets, were sacrificed at each of the following nine time points: days 0, 0.5, 1, 2, 3, 6, 10, 28, and 56.
The levels of lipopolysaccharides in serum, livers, and caecal content were determined using a mouse lipopolysaccharide Elisa kit (BlueGene Biotech, Shanghai, China) according to the manufacturer’s protocol. Caecal content pH was determined using a pH meter (Mettler-Toledo, Beaumont Leys, UK). Fasting blood glucose was measured using blood glucose monitors (Johnson & Johnson, USA). The analysis of serum triglyceride, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, cholinesterase, total bilirubin, and direct bilirubin was performed using an automatic biochemical analyzer (Hitachi 7600, Tokyo, Japan) [29, 30].
BA, SCFA, free fatty acid, and metabolite profile assessment
The metabolite assessment in caecal content was based on the protocols established by our lab [31–35]. All of the samples were run in a randomized order to minimize the systematic analytical error. Three samples were selected randomly from each group and were pooled as quality control samples for metabolite profile assessment. The samples were run in triplicate as analytical replicates.
Each 10-mg of caecal content sample was extracted by a two-step extraction. A 200-μL aliquot of methanol/water (1:1, containing the six internal standards CA-d4, LCA-d4, UDCA-d4, GCA-d4, GCDCA-d4, and glycodeoxycholic acid-d4, at 50 nM each) was added to the sample. The sample was homogenized for 5 min and centrifuged at 13,200 g at 4 °C for 15 min. The supernatant was transferred into a 1.5-mL tube and the sample residue was further extracted by a 200-μL aliquot of methanol/acetonitrile (2:8, containing the six internal standards as the first extraction solvent). After homogenization and centrifugation, the supernatant was transferred to the tube with the first extraction. The extraction mixture was vortexed for 3 min and centrifuged at 13,200 g at 4 °C for 15 min. The supernatant was then transferred to a sampling vial for analysis.
BA analysis was performed on the instrument UPLC/TQMS. The elution solvents were water + 0.01% formic acid (A) and acetonitrile/methanol (19:1) + 0.01% formic acid (B). The elution gradient over 20 min at a flow rate of 450 μL/min was as follows: 0–2 min (20% B), 2–3 min (20–25% B), 3–6 min (25% B), 6–8 min (25–35% B), 8–11.5 min (35% B), 11.5–18 min (35–99% B), 18–19 min (99% B), and 19–20 min (99–20% B). The MS was operated at a negative electrospray ionization mode. The cone and collision energy for each BA used the optimized settings from QuanOptimize application manager (Waters Corp., Milford, MA, USA). One standard calibration solution at 10 different concentration levels contains 45 standards and was tested every 40 samples. The peak annotation and quantitation was performed by TargetLynx application manager (Waters Corp.).
A 500-μL aliquot of 0.005 M aqueous NaOH containing one internal standard (5 μg/mL pentanoic acid-d3) was added to 10 mg of caecal content sample, homogenized for 5 min, and centrifuged at 13,200 g at 4 °C for 15 min. The supernatant was transferred into a 10-mL glass centrifuge tube. A 500-μL aliquot of propanol/pyridine mixture solvent (3:2) and 100 μL of propyl chloroformate were subsequently added to the glass tube. After brief vortexing, the derivatization reaction proceeded under ultrasonication for 1 min. After derivatization, the derivatives were extracted by a two-step extraction with hexane. An aliquot of 300-μL hexane was added to the reaction mixture and the sample was vortexed for 1 min followed by centrifugation at 2,000 g for 5 min. A 300-μL aliquot of derivative extraction (upper hexane layer) was transferred to a sampling vial. The extraction procedure was then repeated by adding 200 μL instead of 300 μL of hexane to the reaction mixture. Another 200-μL aliquot of derivative extraction was transferred to the sampling vial with the first extraction. Anhydrous sodium sulfate (~10 mg) was added to remove traces of water from hexane. The resultant mixture was briefly vortexed prior to analysis.
SCFAs analysis was performed using GC-TOFMS. Derivatives were separated using an HP-5 ms capillary column coated with 5% phenyl/95% methylpolysiloxane (30 m × 250 μm i.d., 0.25 μm film thickness, Agilent J & W Scientific, Folsom, CA, USA). One microliter of derivatives was injected in split mode with a ratio of 10:1, and the solvent delay time was set to 2.2 min. The initial oven temperature was held at 50 °C for 2 min, ramped to 70 °C at a rate of 10 °C/min, to 85 °C at a rate of 3 °C/min, to 110 °C at a rate of 5 °C/min, to 290 °C at a rate of 30 °C/min, and finally held at 290 °C for 8 min. Helium was used as a carrier gas at a constant flow rate of 1 mL/min through the column. The temperatures of the front inlet, transfer line, and electron impact ion source were set at 260, 290, and 230 °C, respectively. The electron energy was –70 eV, and the mass spectral data was collected in a full scan mode (m/z 30–600). One standard calibration solution at seven different concentration levels contains three standards and was tested every five samples.
The raw data were subject to processing, including baseline correction, smoothing, noise reduction, deconvolution, library searching, and area calculation. Compound identification was performed by comparing both MS spectra and retention times with those of standard compounds. The peak area of each derivatized SCFA was calculated using the unique mass selected by ChromaTOF.
Free fatty acids assessment
A 500-μL aliquot of isopropynal/hexane (4:1) with 2% phosphate (2 M) and 10 μL of one internal standard (5 μg/mL of nonadecylic acid-d37) was added to 10 mg of caecal content sample, homogenized for 5 min, and centrifuged at 13,200 g at 4 °C for 15 min. A total of 400 μL supernatant was transferred into a 1.5-mL tube. An aliquot of 800-μL hexane and 300 μL of water were then added to the tube, and the mixture was vortexed for 2 min and centrifuged for 10 min at 12,000 g. An aliquot of 800 μL upper layer was transferred to a new tube and dried under vacuum. The residue was reconstituted with 80 μL of methanol and subjected to analysis.
Free fatty acids were analyzed by UPLC/QTOFMS. The elution solvents were water (A) and acetonitrile/isopropyl (v/v = 80/20, B) with a flow rate of 400 μL/min. The initial gradient was 70% B and kept for 2 min, increased to 75% B in 3 min, increased to 80% in 5 min, increased to 90 in 3 min, increased to 99% in 3 min, and kept at 99% for 5 min before switching back to initial condition. The MS was operated at a positive electrospray ionization mode. One standard calibration solution with 65 free fatty acid standards at 10 different concentration levels was analyzed every five sample injections. The peak annotation and quantitation was performed by TargetLynx application manager (Waters Corp., Milford, MA, USA).
Metabolite profile assessment
A total of 175-μL methanol/chloroform (3:1) and internal standard solution (10 μL of p-chlorophenylalanine in water, 0.1 mg/mL) was added to 10 mg of caecal content sample, homogenized for 5 min, and centrifuged at 13,200 g at 4 °C for 15 min. A 200-μL aliquot of supernatant was transferred to a GC sampling vial and vacuum dried for further TMS derivatization. Methoxyamine (50 μL; 15 mg/mL in pyridine) was added to the dried sample, and the sample was maintained at 30 °C for 1.5 h. N,O-Bis(trimethylsilyl)trifluoroacetamide (50 μL; containing 1% trimethylchlorosilane) was added and the sample was kept at 70 °C for 1 h. The sample was vortexed for 10 sec prior to analysis.
Metabolite profiling was performed on GC-TOFMS. Pooled extraction quality control sample was injected every 10 sample injections. Each 1-μL aliquot of the derivatized solution was injected into the instrument. Separation was achieved on a DB-5 MS capillary column (30 m × 250 μm I.D., 0.25 μm film thickness; (5%-phenyl)-methylpolysiloxane bonded and crosslinked) with helium as the carrier gas at a constant flow rate of 1.0 mL/min. The temperature of injection, transfer interface, and ion source was set to 270, 260, and 220 °C, respectively. The GC temperature programming was set to 2 min isothermal heating at 80 °C, followed by 10 °C/min oven temperature ramps to 140 °C, 4 °C/min to 210 °C, 10 °C/min to 240 °C, and 25 °C/min to 290 °C, with a final 4.5 min maintenance at 290 °C. Electron impact ionization (–70 eV) at full scan mode (m/z 30–600) was used, with an acquisition rate of 20 spectra/s.
Spectral data analysis was performed by ChromaTOF software. Compound identification was performed using our in-house library containing over 1000 mammalian metabolite standards and online available libraries (National Institute of Standards and Technology).
Gut microbe 16S rRNA sequencing
Five caecal content samples of each group were selected for microbiota 16S rRNA analysis. Microbial genome DNA was extracted from samples using a QIAamp DNA stool mini kit (QIAGEN, cat#51504) following the manufacturer’s protocol. Successful DNA isolation was confirmed by agarose gel electrophoresis.
The V4-V5 hypervariable regions of 16S rRNA gene were PCR amplified from microbial genomic DNA harvested from caecal samples and used for the remainder of the study. PCR primers flanking the V4-V5 hypervariable region of bacterial 16S rDNA were designed. The barcoded fusion forward primer was 520 F 5-AYTGGGYDTAAAGNG-3, and the reverse primer was 802R 5-TACNVGGGTATCTAATCC-3. The PCR conditions were as follows: one pre-denaturation cycle at 94 °C for 4 min, 25 cycles of denaturation at 94 °C for 30 s, annealing at 50 °C for 45 s, elongation at 72 °C for 30 s, and one post-elongation cycle at 72 °C for 5 min. The PCR amplicon products were separated on 0.8% agarose gels and extracted from the gels. Only PCR products without primer dimers and contaminant bands were used for sequencing by synthesis. Barcoded V4-V5 amplicons were sequenced using the pair-end method by Illumina Miseq with a six-cycle index read. Sequences with an average phred score lower than 25, ambiguous bases, homopolymer runs exceeding 6 bp, primer mismatches, or sequence lengths shorter than 100 bp were removed. Only sequences with an overlap longer than 10 bp and without any mismatch were assembled according to their overlap sequence. Reads that could not be assembled were discarded. Barcode and sequencing primers were trimmed from sequence reads [30, 36].
Taxon-dependent analysis was conducted using the Ribosomal Database Project classifier , which is a web-based program that assigns 16S rRNA gene sequences to phylogenetically consistent bacterial taxonomy. Bacterial operation taxonomic units (OTU) were generated using the uclust function in QIIME (http://qiime.org/scripts/pick_otus.html), and were counted for each sample to express the richness of bacterial species with an identity cutoff of 97%. The OTU abundance of each sample was generated at the species level. The mean length of all effective bacterial sequences without primers was 223 bp. Simpson indices were calculated by MOTHUR (http://www.mothur.org/) .
All of the physiological, biochemical, metabolite, and microbiota data are collected from different individuals (seven or five per group) as biological replicates. Taxonomy abundance at different ranks was normalized to the summation by each sample. A phylogenetic tree was constructed based on the 16S sequence alignment using clearcut in MOTHUR. Unweighted UniFrac was run using the resulting tree, and PCOA was performed on the resulting matrix . The linear discriminant analysis effect size method was used to compare significant differences in taxa between groups . The Wilcoxon signed-rank and Wilcoxon rank-sum tests were used to compare groups of paired samples and unpaired samples, respectively, and were performed using STATA 12.0 I/C (Statacorp, College Station, TX, USA). Principal component analysis and partial least squares discriminant analysis were carried out in the Simca-P 13.0 software package (Umetrics, Umea, Sweden). Mann–Whitney U tests and Spearman correlation were performed using SPSS 13.0 software. The statistical significance P values were adjusted using a false discovery rate of 0.05.
This work was supported by the National Natural Science Foundation of China (31500954 and 31501079), and Science and Technology Committee of Shanghai Municipality Government (15YF1409100).
Availability of data and materials
The data generated or analyzed during this study are included in this published article, its supplementary information files, and publicly available repositories. The metagenomic raw data are deposited at NCBI under Project SRP111317. The metabolomics raw data are deposited at EBI Metabolights under projects MTBLS545 (metabolome profile), MTBLS546 (targeted short chain fatty acid analysis), MTBLS548 (targeted fatty acid analysis), and MTBLS547 (targeted bile acid analysis).
XZ, AZ, GX, and WJ designed the study. XZ, FH, SL, and YZ performed the animal study and collected samples. XZ, FH, AZ, SL, YZ, and CQ acquired the data for analyses. XZ, FH, AZ, SL, YZ, and TC analyzed the data. XZ, GX, and WJ drafted the manuscript. CR, BD, DL and WJ revised the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559–63.View ArticlePubMedGoogle Scholar
- Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon J. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med. 2009;1(6):6ra14.View ArticlePubMedPubMed CentralGoogle Scholar
- Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med. 2013;34(1):39–58.View ArticlePubMedGoogle Scholar
- Carmody RN, Gerber GK, Luevano Jr JM, Gatti DM, Somes L, Svenson KL, Turnbaugh PJ. Diet dominates host genotype in shaping the murine gut microbiota. Cell Host Microbe. 2015;17(1):72–84.View ArticlePubMedGoogle Scholar
- Islam KB, Fukiya S, Hagio M, Fujii N, Ishizuka S, Ooka T, Ogura Y, Hayashi T, Yokota A. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology. 2011;141(5):1773–81.View ArticlePubMedGoogle Scholar
- Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89(1):147–91.View ArticlePubMedGoogle Scholar
- Devkota S, Wang Y, Musch MW, Leone V, Fehlner-Peach H, Nadimpalli A, Antonopoulos DA, Jabri B, Chang EB. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature. 2012;487(7405):104–8.PubMedPubMed CentralGoogle Scholar
- Floch MH, Binder HJ, Filburn B, Gershengoren W. The effect of bile acids on intestinal microflora. Am J Clin Nutr. 1972;25(12):1418–26.PubMedGoogle Scholar
- Kurdi P, Kawanishi K, Mizutani K, Yokota A. Mechanism of growth inhibition by free bile acids in lactobacilli and bifidobacteria. J Bacteriol. 2006;188(5):1979–86.View ArticlePubMedPubMed CentralGoogle Scholar
- Reddy BS. Diet and excretion of bile acids. Cancer Res. 1981;41(9 Pt 2):3766–8.PubMedGoogle Scholar
- Watanabe M, Horai Y, Houten SM, Morimoto K, Sugizaki T, Arita E, Mataki C, Sato H, Tanigawara Y, Schoonjans K, et al. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J Biol Chem. 2011;286(30):26913–20.View ArticlePubMedPubMed CentralGoogle Scholar
- Salonen A, de Vos WM. Impact of diet on human intestinal microbiota and health. Annu Rev Food Sci Technol. 2014;5:239–62.View ArticlePubMedGoogle Scholar
- Murphy EF, Cotter PD, Healy S, Marques TM, O'Sullivan O, Fouhy F, Clarke SF, O'Toole PW, Quigley EM, Stanton C, et al. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut. 2010;59(12):1635–42.View ArticlePubMedGoogle Scholar
- Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, Takei H, Muto A, Nittono H, Ridlon JM, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol. 2013;58(5):949–55.View ArticlePubMedPubMed CentralGoogle Scholar
- Degirolamo C, Modica S, Palasciano G, Moschetta A. Bile acids and colon cancer: solving the puzzle with nuclear receptors. Trends Mol Med. 2011;17(10):564–72.View ArticlePubMedGoogle Scholar
- Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999;284(5418):1365–8.View ArticlePubMedGoogle Scholar
- Baptissart M, Vega A, Maqdasy S, Caira F, Baron S, Lobaccaro JM, Volle DH. Bile acids: from digestion to cancers. Biochimie. 2013;95(3):504–17.View ArticlePubMedGoogle Scholar
- Barrasa JI, Olmo N, Lizarbe MA, Turnay J. Bile acids in the colon, from healthy to cytotoxic molecules. Toxicol In Vitro. 2013;27(2):964–77.View ArticlePubMedGoogle Scholar
- Lee JY, Arai H, Nakamura Y, Fukiya S, Wada M, Yokota A. Contribution of the 7beta-hydroxysteroid dehydrogenase from Ruminococcus gnavus N53 to ursodeoxycholic acid formation in the human colon. J Lipid Res. 2013;54(11):3062–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Serfaty L, Bissonnette M, Poupon R. Ursodeoxycholic acid and chemoprevention of colorectal cancer. Gastroenterol Clin Biol. 2010;34(10):516–22.View ArticlePubMedGoogle Scholar
- Im E, Martinez JD. Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells. J Nutr. 2004;134(2):483–6.PubMedGoogle Scholar
- Devlin AS, Fischbach MA. A biosynthetic pathway for a prominent class of microbiota-derived bile acids. Nat Chem Biol. 2015;11(9):685–90.View ArticlePubMedPubMed CentralGoogle Scholar
- Woting A, Blaut M. The intestinal microbiota in metabolic disease. Nutrients. 2016;8(4):202.View ArticlePubMedPubMed CentralGoogle Scholar
- Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013;110(22):9066–71.View ArticlePubMedPubMed CentralGoogle Scholar
- Karlsson CL, Onnerfalt J, Xu J, Molin G, Ahrne S, Thorngren-Jerneck K. The microbiota of the gut in preschool children with normal and excessive body weight. Obesity (Silver Spring). 2012;20(11):2257–61.View ArticleGoogle Scholar
- Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, Kayser BD, Levenez F, Chilloux J, Hoyles L, et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut. 2016;65(3):426–36.View ArticlePubMedGoogle Scholar
- Tachon S, Zhou J, Keenan M, Martin R, Marco ML. The intestinal microbiota in aged mice is modulated by dietary resistant starch and correlated with improvements in host responses. FEMS Microbiol Ecol. 2013;83(2):299–309.View ArticlePubMedGoogle Scholar
- Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489(7415):242–9.View ArticlePubMedGoogle Scholar
- Xie G, Wang X, Huang F, Zhao A, Chen W, Yan J, Zhang Y, Lei S, Ge K, Zheng X, et al. Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. Int J Cancer. 2016;139(8):1764–75.View ArticlePubMedPubMed CentralGoogle Scholar
- Xie G, Wang X, Liu P, Wei R, Chen W, Rajani C, Hernandez BY, Alegado R, Dong B, Li D, et al. Distinctly altered gut microbiota in the progression of liver disease. Oncotarget. 2016;7(15):19355–66.View ArticlePubMedPubMed CentralGoogle Scholar
- Zheng X, Xie G, Zhao A, Zhao L, Yao C, Chiu NH, Zhou Z, Bao Y, Jia W, Nicholson JK, et al. The footprints of gut microbial-mammalian co-metabolism. J Proteome Res. 2011;10(12):5512–22.View ArticlePubMedGoogle Scholar
- Zheng X, Chen T, Zhao A, Wang X, Xie G, Huang F, Liu J, Zhao Q, Wang S, Wang C, et al. The brain metabolome of male rats across the lifespan. Sci Rep. 2016;6:24125.View ArticlePubMedPubMed CentralGoogle Scholar
- Zheng X, Qiu Y, Zhong W, Baxter S, Su M, Li Q, Xie G, Ore BM, Qiao S, Spencer MD, et al. A targeted metabolomic protocol for short-chain fatty acids and branched-chain amino acids. Metabolomics. 2013;9(4):818–27.View ArticlePubMedPubMed CentralGoogle Scholar
- Xie G, Wang Y, Wang X, Zhao A, Chen T, Ni Y, Wong L, Zhang H, Zhang J, Liu C, et al. Profiling of serum bile acids in a healthy Chinese population using UPLC-MS/MS. J Proteome Res. 2015;14(2):850–9.View ArticlePubMedGoogle Scholar
- Ni Y, Zhao L, Yu H, Ma X, Bao Y, Rajani C, Loo LW, Shvetsov YB, Yu H, Chen T, et al. Circulating unsaturated fatty acids delineate the metabolic status of obese individuals. EBioMedicine. 2015;2(10):1513–22.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhao W, Wang Y, Liu S, Huang J, Zhai Z, He C, Ding J, Wang J, Wang H, Fan W, et al. The dynamic distribution of porcine microbiota across different ages and gastrointestinal tract segments. PLoS One. 2015;10(2):e0117441.View ArticlePubMedPubMed CentralGoogle Scholar
- Lan Y, Wang Q, Cole JR, Rosen GL. Using the RDP classifier to predict taxonomic novelty and reduce the search space for finding novel organisms. PLoS One. 2012;7(3):e32491.View ArticlePubMedPubMed CentralGoogle Scholar
- Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, Lesniewski RA, Oakley BB, Parks DH, Robinson CJ, et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol. 2009;75(23):7537–41.View ArticlePubMedPubMed CentralGoogle Scholar
- Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol. 2005;71(12):8228–35.View ArticlePubMedPubMed CentralGoogle Scholar
- Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12(6):R60.View ArticlePubMedPubMed CentralGoogle Scholar